This includes technical innovations in glucose monitoring and insulin delivery resulting in improved glycemic control for type-1 diabetes, and more so in view of the increased complexity of the therapeutic background in patients receiving treatment for type 2 diabetes [210]. The gene discussed is INS; the disease is type 1 diabetes mellitus.